Absolute Antibody's Recombinant Technology

Antibody Production Platform

Their HEXpress™ antibody expression platform rapidly produces high-quality antibodies at milligram-to-gram scale. This custom-built production platform includes our proprietary vectors, cloning system, and high-yielding mammalian cell lines. We use serum-free transient expression as a faster, more affordable alternative to stable CHO cell line generation, and can scale up to multi-gram quantities in a matter of weeks.

Their production platform can manufacture recombinant antibodies in any species, isotype or format, including multispecifics and fragments, with high purity and low endotoxin levels. In 2020, this platform enabled them to produce nearly 4,000 different recombinant antibodies, making 180 grams of protein in total. In addition, they’ve used the platform to build their own catalog of more than 8,500 antibodies in recombinant engineered formats. For example, check out one catalog clone (anti-EGFR, or Cetuximab) available in more than 30 different off-the-shelf formats.

They’ve continued to increase their antibody production capacity in recent years, developing custom high-throughput purification robots as well as implementing a third production line that can recombinantly manufacture hundreds of different antibodies per week.

Antibody Engineering Technology

They have developed a proprietary cloning system to enable rapid reformatting of antibodies into almost any format. This allows antibody engineering such as species, isotype or subtype switching; bispecific or trispecific antibodies; antibody fragments; chimerization and humanization; engineered Fc domains; and Fc fusion proteins. Learn more about their engineering services here, or view the 140+ different formats we have created here.

In addition, they don’t just produce existing antibody formats; they create and offer novel antibody engineering technologies to their customers. Their own novel technologies include:

• Fc Silent™ antibodies, which have a genetically engineered Fc domain with key point mutations that abrogate binding of Fc receptors and abolish ADCC effector function.
• AbFab2™ antibody fragments, recombinant Fab2 fragments with a proprietary dimerization motif in place of the hinge region to remove contaminating byproducts and improve antibody stability.
• Prometheus™ antibody humanization, a humanization platform uniquely focused on enhancing antibody manufacturability, leading to increased expression, lower aggregation, and long-term stability and solubility. We have completed more than 60 successful humanization projects to date.

Hybridoma Sequencing Approach

They’ve developed a cutting-edge high-throughput (NGS) approach to hybridoma sequencing that delivers all variable domains present within a hybridoma, as well as a full analysis characterizing the hybridoma’s sequences and any heterogeneity present. The technology works on any species or isotype, and can rescue contaminated or non-viable cells.

Hybridoma sequencing protects valuable antibodies against contamination, genetic drift, accidental loss, and other unforeseen circumstances, securing customers’ antibody supply chains long-term. They have a large capacity and high success rate; over the last two years, they successfully sequenced 1,900 hybridomas.  We also offer customers antibody protein sequencing when the hybridoma is unavailable, as well as a pioneering polyclonal sequencing service. Learn more about our sequencing services here.